Trial Profile

A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golcadomide (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Tafasitamab (Primary) ; Tazemetostat (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors Celgene Corporation

08 Dec 2025 According to Bristol-Myers Squibb media release, data from the trial were presented at the 67th American Society of Hematology (ASH) Annual Meeting.
08 Dec 2025 Results presented in the Bristol-Myers Squibb Media Release
24 Jul 2025 Planned End Date changed from 18 Apr 2027 to 9 Feb 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com